Lipella Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for a multi-center, phase-2a, dose-escalation clinical trial to assess the safety and efficacy of LP-310 in patients with symptomatic oral lichen planus (OLP), a highly morbid condition with no effective treatment. In March 2023, Lipella created a five-member Scientific Advisory Board in Oral Health, made up of a group of highly regarded experts in oral medicine, to focus on the development of LP-310. This team helped craft the clinical strategy and will be involved in the recruitment of high-quality clinical sites.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.725 USD | +1.97% | +0.69% | -28.92% |
Apr. 17 | Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board | CI |
Apr. 09 | Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.92% | 5.1M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+1.78% | 22.18B | |
-16.67% | 21.2B | |
-9.42% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- LIPO Stock
- News Lipella Pharmaceuticals Inc.
- Lipella Pharmaceuticals Inc. Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus